Development Stage: Research-Grade Signal Pathway Assay Development
Short Description
Universal assay for measuring kinase activity (ADP detection).
Brand
SigPath
Development Stage
Research-Grade Signal Pathway Assay Development
Description
The SigPath™ Kinase Assay Kit uses universal ADP detection to screen for kinase inhibitors across diverse signaling pathways. This assay provides a flexible platform for profiling drug candidates against a wide range of kinase targets. It supports high-throughput discovery efforts in oncology and inflammation by measuring the catalytic activity of purified kinases.
Features
Universal ADP detection; Screens for kinase inhibitors across diverse signaling pathways.
Process Relevance
Signal Transduction Screening
Application Stage
Hit-to-Lead Screening
Applications
Universal inhibitor screening for signal transduction kinases.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Detection Method
Fluorescence Detection (Ex 530 nm / Em 585 nm)
Sample Type
All kinases
Research Areas
Signal Transduction; Oncology
Size
400 tests
Data Output Type
Kinetic (Enzyme Activity)
Assay Time
Results in 10 min
LOD
0.01 U/L
Species
All Species
Storage
Store at −20 °C upon receipt to maintain reagent stability. Follow recommended handling procedures to ensure consistent assay performance.
Storage Comment
Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to −20 °C storage after handling. Do not store at elevated temperatures for extended periods.
Expiry Date
6 months under recommended storage conditions to ensure optimal performance.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
Kinases transfer phosphate groups to substrates regulating cellular processes. Dysregulated kinase activity is a major driver of cancer making kinases a primary group of drug targets.